Scarica l'app Stockscreener
9.69
4.25%
-0.43
Precedente Chiudi:
$10.12
Aprire:
$10.25
Volume 24 ore:
1.16M
Relative Volume:
0.55
Capitalizzazione di mercato:
$620.36M
Reddito:
$170.44M
Utile/perdita netta:
$-193.88M
Rapporto P/E:
-2.5812
EPS:
-3.7541
Flusso di cassa netto:
$-126.38M
1 W Prestazione:
-0.41%
1M Prestazione:
-19.12%
6M Prestazione:
-13.17%
1 anno Prestazione:
+13.87%
Intervallo 1D:
$9.635
$10.38
Intervallo di 1 settimana:
$9.175
$10.51
Portata 52W:
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
9.69 | 621.64M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
Diluted shares outstanding of REGENXBIO, Inc. – HAM:RB0 - TradingView
Regenxbio Inc (RGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Price to book ratio of REGENXBIO, Inc. – HAM:RB0 - TradingView
Inventory turnover of REGENXBIO, Inc. – HAM:RB0 - TradingView
Regenxbio Inc (RGNX) Cash Flow - TradingKey
Regenxbio Inc (RGNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Regenxbio Inc (RGNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RGNX|Regenxbio Inc|Price:9.730|Chg%:-0.520 - TradingKey
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? - Stocktwits
REGENXBIO Inc. (RGNX) stock price, news, quote and history - Yahoo Finance Australia
REGENXBIO Inc. Revenue Breakdown – NASDAQ:RGNX - TradingView
Regenxbio Inc (RGNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Matt Wilsey Built a Gene Therapy for His Daughter. He Says the FDA Isn't Ready for What Comes Next. - finance.biggo.com
REGENXBIO Inc. (RGNX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lawsuit alleges Regenxbio misled investors on g... - Pluang
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm - Morningstar
RegenXBio Raises Capital Through Public Equity Offering - The Globe and Mail
(RGNX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Benzinga
REGENXBIO Raises $100 Million in Public Offering of Common Stock and Pre-Funded Warrants - Minichart
REGENXBIO (NASDAQ: RGNX) prices stock and warrant sale, netting $107.8M - Stock Titan
Regenxbio prices expected $100M public offering - The Pharma Letter
Regenxbio (RGNX) Reports Positive Long-Term Results for Gene The - GuruFocus
Frontier tech research, news & data - MLQ.ai
Regenxbio (RGNX) Reports Positive Long-Term Results for Gene Therapy in Eye Conditions - GuruFocus
Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting - Bitget
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting - PR Newswire
RGNX Stock Sinks After $100M Equity Deal Hits Sentiment - timothysykes.com
REGENXBIO Stock Slides After $100M Equity Offering Pricing - timothysykes.com
REGENXBIO Stock Slides After $100M Equity Offering Shock - StocksToTrade
Form 424B5 Regenxbio Inc For: 17 July By Investing.com - Investing.com Australia
Regenxbio prices $100m public offering at $9 per share By Investing.com - Investing.com South Africa
Form 424B5 Regenxbio Inc For: 17 July - Investing.com UK
REGENXBIO (RGNX) Launches $100M Public Offering at $9.00 per Sha - GuruFocus
REGENXBIO stock dips on $100M equity offering - MSN
Regenxbio Shares Fall on $100M Stock, Pre-Funded Warrant Offering - Moomoo
REGENXBIO (NASDAQ: RGNX) launches $100M equity and pre-funded warrant raise - Stock Titan
Regenxbio (RGNX) Launches $100 Million Public Offering - GuruFocus
RGNX Stock Slides As $100M Offering And Legal Heat Hit - StocksToTrade
REGENXBIO Prices $100 Million Public Offering - Moomoo
Crude Oil Surges 4%; Travelers Posts Upbeat Q2 results - Benzinga
RGNX Stock Dips As Equity Offering And Litigation Raise Risk - timothysykes.com
REGENXBIO raises USD 100m amid pivotal year for gene therapy pipeline - AllSci
REGENXBIO files prospectus for up to $100M common stock offering - MSN
Gene Therapy Pioneer REGENXBIO Prices Public Offering, Aims to Raise $100 Million - finance.biggo.com
Regenxbio prices $100m public offering at $9 per share - Investing.com
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants - PR Newswire
Why is Regenxbio stock falling sharply today? - Investing.com
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regenxbio Inc Azioni (RGNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Sale |
13.64 |
2,161 |
29,476 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
7.86 |
36,725 |
288,658 |
249,734 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Sale |
12.86 |
36,725 |
472,284 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jun 29 '26 |
Sale |
11.04 |
19,608 |
216,472 |
213,009 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):